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Therapeutic Use of Ginkgo Biloba 
Amala Guha 
Department of Medicine, University of Connecticut Health Center, 
Farmington CT, USA 
ABSTRACT: Gingko biloba, one of the most popular herbs in the USA is known for its various therapeutic uses and is now well researched 
for its various active compounds. Although originally grown in Asia, the tree is distributed all over the world. Leaves, bark, roots all have 
therapeutic properties and are used for various illnesses like asthma, circulatory ailments and cognitive support or dysfunction. 
History and medicinal use of Ginkgo 
Ginkgo biloba, one of the world's oldest living deciduous trees (I), contains a diverse range of pharmacologically active com- 
pounds which has made it an important therapeutic agent of traditional medicine for thousands of years. The plant is a gym- 
nosperm native to eastern China currently distributed throughout the world, primarily in northern temperate climates (2). Until 
the early 1700s the tree grew primarily in China and other part of Asia; hence Chinese medical traditions have made extensive 
use of ginkgo since 2800 BCE (3). Its leaves, fruits and roots contain medically useful components (4,5). The leaf and fruit- 
based formulations are the most commonly used Ginkgo preparations in Chinese herbal medicines. Therapeutic applications 
include, treatment of asthma and other respiratory problems; infectious diseases such as tuberculosis and gonorrhea; circula- 
tory ailments; and a diverse range of other disorders. In China and other Asian cultures, including Ayurvedic medicine of In- 
dia, medicinal use of Ginkgo biloba has continued since ancient times as a mainstay of accepted medical treatment (6). 
Conversely ginkgo-based formulations have been utilized in the United States and other Western nations since the 1960s after 
the development ofa methodology for isolating and making commercially available the subcomponents of the plant (7). In the 
past decade the use of Ginkgo as a health supplement and alternative to prescription formulations has increased substantially 
among Americans (8). Generally it is sold as a standardized extract of dried leaves (EGb761), containing 24% ginkgo- 
flavonol glycosides and 6% terpene lactones in edible caplet form (9,lO). Reasons for self-administration of this herb vary 
widely, depending on desired health-related outcomes. Three major areas of health that are reputed to be improved by 
Ginkgo, are broadly grouped into (i) Neurological (ii) Circulatory and (iii) Sexual effects. 
Enhanced cognition and neuroprotective effects. Traditionally, Ginkgo is known to contribute to enhanced memory, ability 
to focus, attention, alertness, and overall improved mental acuity. In keeping with tradition, ginkgo-based products are cur- 
rently marketed as enhancers of neurocognitive abilities, in addition to other aspects of general health. This claim has proven 
valid in a number of investigations. For example, cohorts of healthy individuals administered neuropsychological testing be- 
fore and following treatment with EGb761 (ginkgo extract) exhibited superior speed of information processing, working mem- 
ory and executive decision-making as a result of EGb761 ingestion (1). The therapeutic potential of ginkgo was further vali- 
dated in clinical trials of EGb761 in patients with impaired central nervous system (CNS) due to disease or injury. In these 
studies the extract has been shown to significantly improve the cognitive function of disorders including age-associated dete- 
rioration of the brain (1 1); hypoxia-associated neurological injury (12); Alzheimer's disease (13); and cardiovascular accident 
(CVA)/stroke (14). The growing body of information on therapeutic application of Ginkgo biloba through clinical trials has con- 
sistently demonstrated significant improvements in CNS function (1 5). Collectively, results of these studies suggest that the 
extracts of this plant may become an important component in the management of CNS disorders. It is nevertheless known 
that the whole extract of the plant (EGb 761) induces changes such as reversal of age-related depletion in brain chemicals 
(alpha l-adrenergic, 5-HTlA) and allows extended retention of the brain fiber (hippocampal mossy fiber system) (1 1). These 
outcomes, along with the general phenomenon of neuroprotection mediated by ginkgolides may be substantially due to anti- 
oxidant activities of the terpeneoid ginkgolides (Ginkgo subcomponents) (1 6). Other biochemical properties exhibited by gink- 
golides (Table 1) may also contribute to neuroprotection. 
Effects on atherosclerotic and ischemic disease: Common medicinal application to which ginkgo has been traditionally 
applied was in the treatment of poor circulation associated with a wide range of diseases. In the early 1980s, a picture of how 
extracts of the plant acted to improve circulatory function began to emerge. Also, it was discovered in animal studies that 
platelet aggregation leading to clot formation in the peripheral vasculature could be suppressed by pretreatment with 
ginkgolides (17). This effect was also validated in humans with the demonstration that patients suffering from arteriosclerotic 
disorders manifested lower collagen induced platelet-aggregation when treated with Ginkgo extract, than a mock-treated 
control cohort (18), raising the possibility that ginkgolides might be useful in prevention of peripheral arterial occlusive disease 
and related complications. 
Components of Ginkgo biloba were found to have a potent capacity to antagonize the effects of platelet activating factor (PAF) 
(19), a mediator of inflammation, which causes vasoconstriction through its action on vascular endothelial cells, promoting 
inflammation-associated damage, ischemia/reperfusion injury and occlusive pathologies. The capacity of ginkgo extract to act 
as a PAF antagonist and inhibit clot formation, partly explains the beneficial effects the herb is known to have on circulatory 
function. As these aspects of Ginkgo's pharmacological properties became clearer, ginkgo became the subject of an 
increasing number of clinical trials to improve the outcome of vascular diseases. Many of these have met with a considerable 
degree 
of success. These include indications that Ginkgo biloba extract may inhibit the progression of age-related macular 
degeneration (20); cardiac or peripheral ischemia (15), tinnitus (21); obstructive arteriosclerosis and ischemia-reperfusion 
injury (22); and inflammation associated with trauma or disease (14). Components of Ginkgo biloba have been shown to 
positively affect the outcome of organ transplant surgery. Significantly, J. Grino et a1 demonstrated in 1994 that this 
compound is capable of decreasing the incidence of post-transplant renal failure in patients receiving kidney transplants (23). 
The reduction in inflammation-associated mechanisms of graft rejection by ginkgolide B (23) suggests that extracts of the plant 
may become a valuable adjuvant therapy to currently used post-transplant immunosuppressive strategies. 
Treatment of sexual dysfunction: Extracts of Ginkgo biloba have been proven effective in treatment of sexual dysfunction, 
particularly when the condition is induced by administration of anti-depressant medication (24). EGb761 administered orally to 
patients being treated with antidepressants resulted in improved libido, with a 4-6 week regimen of ginkgo necessary for rever- 
sal of depressant-induced sexual side effects (24,25). The sexual libido-enhancing effects of ginkgo have been validated in 
studies of other populations including pre- and postmenopausal women (26); and atherosclerotk males experiencing erectile 
dysfunction (27). The cellular and physiologic mechanisms responsible for these effects remain poorly defined at the time of 
this writing. It has been known that ginkgo-mediated effects include increased blood flow to the genitalia; (24,25). 
Chemical and pharmacological properties of ginkgolides : Extracts of ginkgo may be used in a broad spectrum of clini- 
cal applications that could be neurological, hemodynamic, metabolic or immunological in nature. This extensive range of 
therapeutic utility is due to the diverse activity of individual subcomponents (ginkgolides) produced by the plant. 14 major 
pharmacologically active subcomponents of Ginkgo biloba have been identified (Table 1). These include 8 flavonoid com- 
pounds that are polyphenolic metabolites, widely distributed in vascular plants. They have analgesic properties and are also 
useful for treatment of inflammation. Two of these, bilobetin and ginkgetin, are shown to be potent anti-inflammatory (28) and 
therefore have potential for treatment of inflammatory diseases. Ginkgo biloba also contains 6 terpene lactones with antioxi- 
dant properties (29) which are potentially valuable as anti-inflammatory agents. The terpene lactone ginkgolides block PAF 
activity in a manner, which affects the same biological pathways that are sensitive to calcineurin-inhibitory drugs, such as Cyc- 
losporin A and FK506 (30,31,32), offering possibilities for their use in post-transplant Immunosuppression. Ginkoloide terpi- 
nes are also powerful antioxidants, which further contribute to control of inflammation by quenching reactive oxygen metabo- 
lites (33). The beneficial effects of ginkgo are thus attributable to mechanisms acting separately or in concert, as a result of 
the unique properties of each component. The biological activities of ginkgolides are summarized below (Table 1): 
Limitations of Ginkgo as a therapeutic agent and potential for future use: The diverse range of pharmacological activi- 
ties exhibited by components of Ginkgo biloba and the very promising results of human clinical trials both of the extract and 
individual ginkgolides, suggest that ginkgo-based pharmacotherapy has the potential to substantially augment current ap- 
proaches to treatment of a number of serious and widespread diseases. This is particularly true for CNS-related disorders, 
inflammation and diseases of the microvasculature. Clinical advantages to application of this plant are further augmented by 
the known low incidence of toxicity and side effects associated with its use; even at high dosage (34,24). Despite these ad- 
vantages, Ginkgo biloba suffers from a major drawback with respect to its broad application as a basis for therapeutic agents. 
Whereas both the extract and the individual ginkgolides have been shown to positively affect the outcome of many disease 
conditions, in no case is ginkgo alone sufficient to affect a cure. Nevertheless, recent studies have demonstrated that the 
most promising clinical application for this plant may be as an adjunct for traditional approaches to treatment of a number of 
diseases. 
Ginkgo-augmented adjuvant therapy for neurocognitive disorders: Ginkgo extracts have been used to potentiate the 
effects of other herbal preparations. As an example it has been demonstrated that the therapeutic effectiveness of Panax 
ginseng extracts may be substantially improved by co-administration of this herb together with ginkgo extract. Extracts of 
ginseng root are known to improve neuropsychological measures in humans (35) and are commercially available for this pur- 
pose. The plant contains triterpene glycosides with known neuroprotective properties (36), which are believed to mediate its 
effects on memory and cognition (37). When a blend of ginseng and ginkgo were tested in animal models, it was found to be 
superior to either agent alone in enhancement of these attributes (38). Human clinical trials have confirmed this and show that 
combined therapy using extracts of both ginseng and ginkgo exhibit substantial memory-enhancing properties in healthy, mid- 
dle-aged subjects (37). This demonstration of ginkgo-mediated augmentation of a clinical outcome by another agent 
(ginseng) underscores the utility of ginkgo extracts in adjuvant therapy. Whereas Ginkgo alone often may not be adequate to 
satisfactorily remediate a particular medical problem, its augmentative effect considerably boosts the action of other agents. 
It is in this arena that use of specific ginkgolides as adjuncts to conventional treatment hold enormous potential. An important 
case-in-point is Alzheimer's disease. Development of the disorder involves progressive loss of neurocognitive function, 
brought about by deposition of short amyloid peptides in the brain of afflicted individuals, which interact destructively with 
neurons. (39). Recently it has been shown that the non-steroidal anti-inflammatory drug (NSAID) ibuprophen and 
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have the potential to inhibit and perhaps prevent onset of Alzheimer's in susceptible individuals (40). It is also known that 
Ginkgo biloba alleviates neurocognitive symptoms of the disease; in fact placebo-controlled clinical trials of Ginkgo extract 
demonstrate a therapeutic effect similar to prescription drugs such as tacrine or donepezil, with very low associated toxicity or 
side effects to patients (6). It is thus possible that combined treatment with both agents may act synergistically to prevent its 
onset or decrease its severity. It has been shown that the calcineurin-inhibitory immunosuppressive drugs FK506 and 
Cyclosporin-A were capable of inhibiting graft rejections in transplantation. The toxicity of these drugs makes it difficult to use 
them for long-term. Recently, it was demonstrated (in animal model) that extract of Ginkgo biloba, EGb761, decreased 
cardiac arrhythmias and improved cardiac function when used together with FK506 (30). These observations are now being 
explored in our (Dr. Guha's) laboratory. 
Table 1. SUeCOMPONENTS OF GINKGO BILOBA: 14 pharmacologically active ginkgolides characterized with respect to 
their physical, chemical and biological properties 
MAJOR PHARMACOLOGICAL 
PROPERTIES COMPOUND CHEMICAL SPECIES 
terpene lactone 
GA, ginkgolide A, BN52020, 
CAS 15291 -75-5 
PAFR antagonist, but no 
apparent antioxidant properties 
GB, ginkgolide B, BN52021, 
CAS 1 5291 -77-7 
PAFR antagonist, with antioxidant properties 
terpene lactone 
terpene lactone 
PAFR antagonist, with antioxidant properties 
GC, ginkgolide C 
PAFR antagonist, with antioxidant properties 
GJ, ginkgolideJ terpene lactone 
terpene lactone 
sesquiterpene 
PAFR antagonist, with antioxidant properties 
GM, ginkgolideM 
Primarily an antioxidant, poor PAFR proper- 
ties Bilobalide 
lnhibits cyclooxygenase without affecting 
lipoxygenase. Will inhibit PLA-2, strong in- 
hibitor of CAMP-phosphodiesterase Amentoflavone flavonoid 
lnhibits PLA-2, in turn inhibiting the produc- 
tion to TNF-a, iNOS and inducible cyclooxy- 
ganase (COX-2), moderate inhibitor of CAMP 
phosphodiesterase Bilobetin 
Sequoiaflavone 
flavonoid 
flavonoid 
Moderate inhibitor of cAMPphosphodi- 
esterase 
lnhibits PLA-2, in turn inhibiting the produc- 
tion of TNF-a, iNOS and inducible cyclooxy- 
genase (COX-2). Inhibits pathogenesis of 
arthritis Ginkgetin flavonoid 
Weak inhibitor of CAMP-phyosphodi-esterase 
irreversible inhibitor of lymphocyte prolifera- 
tion lsoginkgetin 
Sciadopitysin 
flavonoid 
flavonoid 
Irreversible inhibitors of lymphocyte prolifera- 
tion 
lnhibitor of lymphocyte proliferation. 
flavonoid 
Inhibitor of lymphocyte proliferation, PLA-2 
inhibitor, Moderate inhibitor of camp- 
phosphdiesterase Quercetin flavonoid 
Toxicity: Ginko biloba extracts are known to be safe. However, gastrointestinal discomforts, headaches and dizziness have 
been reported. Ginko leaf extracts are well tolerated as opposed to Ginko fruit derived supplements. 
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